Technical Analysis for GLPG - Galapagos NV

Grade Last Price % Change Price Change
D 82.44 -0.84% -0.70
GLPG closed down 0.84 percent on Thursday, April 22, 2021, on 36 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical GLPG trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Overbought Strength 0.00%
Weak + Overbought Other 0.00%
Inside Day Range Contraction 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 50 DMA Bullish -0.84%
BB Squeeze Ended Range Expansion -0.84%
Above Upper BB Strength -0.84%
Older End-of-Day Signals for GLPG ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits about 2 hours ago
Possible Inside Day about 15 hours ago
60 Minute Opening Range Breakout about 16 hours ago
50 DMA Support about 19 hours ago
Down 1% about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Galapagos NV Description

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Clinical Development Acid Autoimmune Diseases Inflammation Monoclonal Antibodies Inflammatory Disease Inflammatory Diseases Rheumatoid Arthritis Psoriasis Inflammatory Bowel Disease Osteoarthritis Ulcer Cystic Fibrosis Colitis Ulcerative Colitis Glaxosmithkline Fatty Acid Janus Abdominal Pain Arthritis Janus Kinase Treatment Of Inflammation Treatment Of Inflammatory Disease Treatment Of Inflammatory Diseases Mechel Morphosys

Is GLPG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 233.14
52 Week Low 74.51
Average Volume 343,712
200-Day Moving Average 122.51
50-Day Moving Average 81.55
20-Day Moving Average 78.65
10-Day Moving Average 79.66
Average True Range 2.06
ADX 18.44
+DI 33.66
-DI 27.56
Chandelier Exit (Long, 3 ATRs ) 76.96
Chandelier Exit (Short, 3 ATRs ) 80.70
Upper Bollinger Band 82.37
Lower Bollinger Band 74.93
Percent B (%b) 1.01
BandWidth 9.46
MACD Line -0.41
MACD Signal Line -1.29
MACD Histogram 0.8855
Fundamentals Value
Market Cap 5.39 Billion
Num Shares 65.3 Million
EPS -1.69
Price-to-Earnings (P/E) Ratio -48.90
Price-to-Sales 14.69
Price-to-Book 2.45
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 83.94
Resistance 3 (R3) 83.96 83.49 83.69
Resistance 2 (R2) 83.49 83.10 83.48 83.61
Resistance 1 (R1) 82.96 82.87 82.73 82.94 83.52
Pivot Point 82.49 82.49 82.37 82.48 82.49
Support 1 (S1) 81.96 82.10 81.73 81.94 81.36
Support 2 (S2) 81.49 81.87 81.48 81.27
Support 3 (S3) 80.96 81.49 81.19
Support 4 (S4) 80.94